ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics (Q28084565)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25699077%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

review article

1 reference

title

ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics (English)

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25699077%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25699077%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Grégoire B Morand

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25699077%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Moulay A Alaoui-Jamali

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25699077%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Sabrina Daniela da Silva

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25699077%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

language of work or name

1 reference

4 February 2015

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25699077%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

published in

Frontiers in Genetics

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25699077%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

6

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25699077%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

17

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25699077%20AND%20SRC:MED&resulttype=core&format=json

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

1 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Comprehensive molecular portraits of human breast tumours

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Humanization of an anti-p185HER2 antibody for human cancer therapy

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

The deaf and the dumb: the biology of ErbB-2 and ErbB-3

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Chromosome 7p11.2 (EGFR) variation influences glioma risk

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

ERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Single Nucleotide Polymorphisms Associated with MicroRNA Regulation.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

The EGFR family: not so prototypical receptor tyrosine kinases

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Epidermal growth factor receptor gene polymorphisms are associated with prognostic features of breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Association between -276 C/T polymorphism of the ERBB3 gene and lung cancer risk in a Korean population

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

ErbB receptors and the development of the nervous system

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Ligand-induced ErbB receptor dimerization

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316710

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

2 June 2018

1 reference

https://api.crossref.org/works/10.3389%2FFGENE.2015.00017

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFGENE.2015.00017

Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFGENE.2015.00017

Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFGENE.2015.00017

Purified EGF receptor-kinase interacts specifically with antibodies to Rous sarcoma virus transforming protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFGENE.2015.00017

Lack of replication for the association between HER2 I655V polymorphism and breast cancer risk: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFGENE.2015.00017

Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFGENE.2015.00017

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFGENE.2015.00017

Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFGENE.2015.00017

Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFGENE.2015.00017

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFGENE.2015.00017

Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFGENE.2015.00017

Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFGENE.2015.00017

A novel polymorphism in the promoter region of ERBB4 is associated with breast and colorectal cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFGENE.2015.00017

EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFGENE.2015.00017

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the hum

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFGENE.2015.00017

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFGENE.2015.00017

The ERBB network: at last, cancer therapy meets systems biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFGENE.2015.00017

The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer

21 January 2018

1 reference

12 December 2020

Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma

1 reference

12 December 2020

A single nucleotide polymorphism in the transmembrane domain coding region of HER‐2 is associated with development and malignant phenotype of gastric cancer

1 reference

12 December 2020

Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity

1 reference

12 December 2020

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase

1 reference

12 December 2020

Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells

1 reference

12 December 2020

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

1 reference

12 December 2020

Identifiers

DOI

10.3389/FGENE.2015.00017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25699077%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25699077%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

PubMed publication ID

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25699077%20AND%20SRC:MED&resulttype=core&format=json